IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11559618 B1

PDFFull Text
Date of Patent:
Jan. 24, 2023

Filed:

May. 02, 2022

Formulations and methods for direct sodium removal in patients having severe renal dysfunction

Applicant:

Sequana Medical NV, Ghent, BE;

Inventors:

Jeffrey Testani, Guilford, CT (US);

Christopher McIntyre, Ontario, CA;

Ian Crosbie, London, GB;

Oliver Goedje, Strasslach, DE;

Assignee:

Sequana Medical NV, Ghent, BE;

Attorneys:

Eversheds Sutherland (US) LLP

Christopher C. Bolten

Nicola A. Pisano

Primary Examiner:

Robert A Wax

Assistant Examiner:

Randeep Singh

Int. Cl.
CPC ...
A61M 1/28 (2006.01); A61P 7/08 (2006.01); A61K 33/14 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/7004 (2006.01); A61K 31/716 (2006.01); A61M 27/00 (2006.01); A61M 31/00 (2006.01); A61L 2/00 (2006.01);
U.S. Cl.
CPC ...
A61M 1/282 (2014.02); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 31/7004 (2013.01); A61K 31/716 (2013.01); A61K 33/14 (2013.01); A61M 1/28 (2013.01); A61M 1/285 (2013.01); A61M 1/287 (2013.01); A61M 27/002 (2013.01); A61M 31/002 (2013.01); A61P 7/08 (2018.01); A61L 2/0047 (2013.01); A61L 2202/21 (2013.01); A61M 2205/18 (2013.01); A61M 2205/3317 (2013.01); A61M 2205/3337 (2013.01); A61M 2205/3344 (2013.01); A61M 2205/3368 (2013.01); A61M 2205/3379 (2013.01); A61M 2205/3569 (2013.01); A61M 2205/3576 (2013.01); A61M 2205/502 (2013.01); A61M 2205/52 (2013.01); A61M 2205/587 (2013.01); A61M 2205/6009 (2013.01); A61M 2205/70 (2013.01); A61M 2205/8206 (2013.01); A61M 2205/8243 (2013.01); A61M 2209/086 (2013.01); A61M 2209/088 (2013.01); A61M 2210/1017 (2013.01); A61M 2210/1085 (2013.01);
Abstract

A direct sodium removal ('DSR') infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.

Find Patent Forward Citations

Loading…